Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

Phase 3 pivotal REVIVE study data of VIVUS' avanafil for ED presented at 2010 AUA

VIVUS, Inc. today announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), were presented at the American Urological Association (AUA) 2010 Annual Meeting.

2 Jun 2010

Men with ED are at increased risk of high CACS: Researchers

In the largest study to date evaluating erectile dysfunction and coronary artery calcification, researchers at Mount Sinai School of Medicine have determined that men with ED are at a significantly increased risk of high coronary artery calcification scores, a known predictor of future cardiovascular events.

2 Jun 2010

AMS issued U.S. patent covering surgical methodology for implanting AdVance Male Sling

American Medical Systems, a leading provider of world-class devices and therapies for both male and female pelvic health, announced today that the United States Patent and Trademark Office has issued U.S. Patent Number 7,686,760 covering the surgical methodology for implanting the AMS AdVance® Male Sling. This patent provides AMS with broad patent coverage on transobturator surgical procedures to treat male incontinence.

29 May 2010

New GreenLight XPS Laser System launched for treatment of BPH

American Medical Systems, a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the launch and immediate availability of its new GreenLight XPS (Xcelerated Performance System) for laser treatment of benign prostatic hyperplasia or enlarged prostate.

29 May 2010

VIVUS to present phase 3 data on avanafil for treatment of ED at AUA 2010

VIVUS, Inc. today announced that phase 3 data on avanafil, a next generation oral phosphodiesterase type 5 inhibitor therapy being investigated for the treatment of erectile dysfunction, will be presented next Tuesday at the American Urological Association 2010 Annual Meeting in San Francisco, California.

28 May 2010

VIVUS first-quarter 2010 total revenues decline: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring VIVUS Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

28 May 2010

Study demonstrates need for understanding societal, economic impact of growing medicalization

Menopause. Normal pregnancy. Infertility. ADHD. Erectile dysfunction. Over the last several decades, these conditions have come to be defined and treated as medical problems. They've been "medicalized." In the first study of its kind in the current issue of Social Science and Medicine, Brandeis researchers used national data to estimate the costs of these and a handful of other common conditions on escalating U.S. healthcare spending.

19 May 2010

Significant proportion of men with ED exhibit early signs of CAD: Review

International experts are calling for all men experiencing impotence to undergo thorough medical assessments, after an extensive review showed that a significant proportion of men with erectile dysfunction exhibit early signs of coronary artery disease.

19 May 2010

Research efforts needed to identify optimal treatments for sexual dysfunction in people with CKD

Despite the very high rate of problems with sexual function among people with chronic kidney disease (CKD), little is known about the best treatment approaches in this group of patients, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

14 May 2010

Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will initiate a Phase IIb clinical trial for ZoraxelTM in the treatment of erectile dysfunction (ED).

13 May 2010

Data on Qnexa to be presented at World Congress on CODHy in Prague

VIVUS, Inc. today announced that data on Qnexa, an investigational drug candidate, will be presented at the 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension in Prague, Czech Republic.

13 May 2010

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

New research by scientists at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute suggests that a drug currently approved to treat erectile dysfunction may significantly enhance the delivery of the anti-cancer drug Herceptin to certain hard-to-treat brain tumors.

10 May 2010

Creator of California Tay-Sachs Disease Prevention Program among the honorees

A mere 40 years ago, parents didn't know they were carriers of the Tay-Sachs disease until after they'd given birth to a child with this fatal genetic disorder.

7 May 2010

Warner Chilcott reports 209.5% increase in first-quarter 2010 revenues

Warner Chilcott plc today announced its results for the quarter ended March 31, 2010. Revenue in the quarter was $761.3 million, an increase of $515.3 million, or 209.5%, over the prior year quarter.

7 May 2010

Today's Opinions and Editorials: The end of insurance rescissions, lessons from the health care rollout and the deficit panel's tough decisions

A lot of people laughed when Sue Lowden, the Nevada Republican running for the U.S. Senate, suggested last month that people start paying for their medical care with chickens. I didn't (Jonathan Cohn, 5/3).

3 May 2010

SGB procedure holds potential promise for PTSD treatment

Walter Reed Army Medical Center in Bethesda, MD, has published case reports detailing the successful treatment of combat-related post-traumatic stress disorder with a stellate ganglion block.

3 May 2010

Men with erectile dysfunction, low testosterone at higher risk of death from cardiovascular disease

Research presented at the European Congress of Endocrinology shows for the first time that men with erectile dysfunction and low testosterone have a higher than normal risk of dying from cardiovascular disease. Further work from the same research group shows that obesity is also associated with an impairment of blood flow to the penis, which in turn is also associated with cardiovascular disease in men with erectile dysfunction.

27 Apr 2010